New: Clinical trial search, funded by the National Cancer Institute
New: NCI-funded clinical trial search
Community
Tools
Company
Support
Sign in
Join for Free
Join for Free
Community
Could we use gilteritinib in R/R AML patients who harbor non D835/1836 FLT3 TKD mutations?
The ADMIRAL trial only included these two point mutations in TKD.
Good Question
Save
Request Answers
Share
Add Answer
